Zoetis Inc.
Zoetis Reports 2025 Financial Results and Provides 2026 Guidance
Summary
Zoetis Inc. reported a 3% increase in revenue to $2.4 billion for Q4 2025 and a 2% increase to $9.5 billion for full year 2025. Net income increased by 4% to $603 million for Q4 2025 and by 8% to $2.7 billion for full year 2025. The company provided guidance for full year 2026, expecting revenue between $9.825 billion to $10.025 billion and adjusted diluted EPS between $7.00 to $7.10.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement